Natera Q4 2022 Earnings Presentation - February 2023

Natera reported $820.2M in FY22 revenues with 37% growth and processed 2.07M tests. The company guides 2023 revenue of $980M-$1B while reducing cash burn by $150M, with significant expansion in oncology testing and multiple new clinical guideline endorsements for Signatera and carrier screening products.